Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease.

Tiklamalar: 306
ID: 125659
2020
Makale Kalitesi ve Performans Metrikleri
Genel Kalite
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
Yapay Zeka Kalite Degerlendirmesi
Analiz edilmedi
Readership in this journal
Emerging

Ranked #117 of 406 articles by views in European journal of medicinal chemistry

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 406 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Ozet
Here we reported novel apigenin-rivastigmine hybrids were rationally designed and synthesized by the multi-target-directed ligands (MTDLs) strategy, their activity in vitro results revealed that compound 3d showed significant antioxidant potency (ORAC = 1.3 eq), and it was a reversible huAChE (IC = 6.8 μM) and huBChE (IC = 16.1 μM) inhibitor. 3d also served as a selective metal chelator, and it significantly inhibited and disaggregated self-mediated and Cu-mediated Aβ aggregation, and also inhibited hAChE-mediated induced Aβ aggregation. Compound 3d exhibited remarkable neuroprotective effect and hepatoprotective activity. In addition, compound 3d presented favourable blood-brain barrier penetration in vitro and drug-like property. Further, the in vivo assay displayed that 3d indicated remarkable dyskinesia recovery rate and response efficiency on AD zebrafish, and exhibited surprising protective effect on Aβ-mediated zebrafish vascular injury. More importantly, 3d did not indicate obvious acute toxicity at dose up to 2000 mg/kg, and could improve scopolamine-induced memory impairment. Subsequently, the regulation of multi-targets for 3d were further confirmed through transcriptome sequencing of brain hippocampi, which also offered novel potential targets and opened a new way to treat Alzheimer's disease. More interestingly, the metabolism of 3din vitro indicated that 4 metabolites in rat liver microsome metabolism, 2 metabolites in human liver microsome metabolism, and 4 metabolites in intestinal flora metabolism, which offered supports for the preclinical study of 3d. Overall, this study exhibited that compound 3d was a promising advanced compound targeted multiple factors associated with AD.
Referans Anahtari
sang2020apigeninrivastigmineeuropean Kullanarak makale yazarken otomatik alinti icin bu anahtari kullanin SciMatic Makale Yoneticisi veya Tez Yoneticisi
Yazarlar Sang, Zhipei;Wang, Keren;Shi, Jian;Cheng, Xinfeng;Zhu, Gaofeng;Wei, Rongrui;Ma, Qinge;Yu, Lintao;Zhao, Yiyang;Tan, Zhenghuai;Liu, Wenmin;
Dergi European journal of medicinal chemistry
Yil 2020
DOI
S0223-5234(19)31110-9
URL
Anahtar Kelimeler
alzheimer’s disease transcriptome sequencing metabolism in vitro multi-function agents apigenin-rivastigmine hybrids in vivo assay

Atiflar

Atif bulunamadi. Atif eklemek icin yoneticiyle iletisime gecin: info@scimatic.org

Yorumlar

Henuz yorum yok. Bu makaleye ilk yorumu siz yapin.